Net Loss Per Share (Tables)

12 Months Ended

Dec. 31, 2022

Earnings Per Share [Abstract]

Schedule of Comparison of Basic and Fully Diluted Net Loss Per Share

The “Net loss per share - attributable to PAVmed Inc. - basic and diluted” and “Net loss per share - attributable to PAVmed Inc. common stockholders - basic and diluted” - for the respective periods indicated - is as follows:

	Years Ended December 31,
	2022			2021
Numerator
Net loss - before noncontrolling interest	$	(103,238	)	$	(56,126	)
Net loss attributable to noncontrolling interest		14,255			5,779
Net loss - as reported, attributable to PAVmed Inc.	$	(88,983	)	$	(50,347	)
Series B Convertible Preferred Stock dividends – earned	$	(281	)	$	(283	)
Net loss attributable to PAVmed Inc. common stockholders	$	(89,264	)	$	(50,630	)
Denominator
Weighted average common shares outstanding, basic and diluted		89,076,078			77,515,767
Net loss per share
Basic and diluted
Net loss - as reported, attributable to PAVmed Inc.	$	(1.00	)	$	(0.65	)
Net loss attributable to PAVmed Inc. common stockholders	$	(1.00	)	$	(0.65	)

Schedule of Antidilutive Securities Excluded from Computation of Diluted Earnings Per Share

	December 31,
	2022		2021
Stock options and restricted stock awards		12,543,655		10,386,864
Series Z Warrants		11,937,450		11,937,455
Series W Warrants		—		377,873
Series B Convertible Preferred Stock		1,205,759		1,113,919
Total		25,686,864		23,816,111